Revance Therapeutics (RVNC) Gets H.C. Wainwright Civerage with $25 Target; Moneta Group Investment Advisors Lowered General Electric Co Com (GE) Holding By $1.60 Million

General Electric Company (NYSE:GE) Logo

New York: Revance Therapeutics (NASDAQ:RVNC) coverage was was started with a “Buy” rating and $25 price target at H.C. Wainwright. H.C. Wainwright’s target price means upside of 40.61% from the company’s previous stock close.

Moneta Group Investment Advisors Llc decreased General Electric Co Com (GE) stake by 71.33% reported in 2018Q3 SEC filing. Moneta Group Investment Advisors Llc sold 145,404 shares as General Electric Co Com (GE)’s stock declined 44.60%. The Moneta Group Investment Advisors Llc holds 58,447 shares with $660,000 value, down from 203,851 last quarter. General Electric Co Com now has $90.20 billion valuation. The stock increased 3.91% or $0.39 during the last trading session, reaching $10.37. About 98.94 million shares traded. General Electric Company (NYSE:GE) has declined 60.87% since February 14, 2018 and is downtrending. It has underperformed by 60.87% the S&P500. Some Historical GE News: 02/04/2018 – Veritas Capital to acquire a GE Healthcare unit for $1 billion; 04/04/2018 – GE’s AGP Solution Installed on 435 Units in 39 Countries; 13/03/2018 – Industrials Sink as GE Cuts Executive Bonuses – Industrials Roundup; 20/04/2018 – GENERAL ELECTRIC CO – MAKING SIGNIFICANT PROGRESS ON THE $20 BILLION OF DISPOSITIONS PLANNED FOR 2018 & 2019; 23/03/2018 – Boeing set to win wide-body jet order from American; 26/03/2018 – GE POWER – CO & FIELDCORE SUCCESSFULLY RESTARTED METAHARA SUGAR FACTORY IN ETHIOPIA, 7 MONTHS AFTER SEVERE DAMAGE TO PLANT BY A THUNDERSTORM; 16/05/2018 – Southwest Sends Engine Fan Blades to GE for Further Inspection; 23/03/2018 – USDA-Foreign Agr: Japan: Japan Set to Modify its GE Food Labeling System – March 23, 2018; 12/03/2018 – Medical Imaging Market in APAC: Analysis & Forecasts Report (2017-2021) with Key Players GE Healthcare, Koninklíjke Philips, Siemens Healthcare, Toshiba Medical Systems, and Fujifilm – ResearchAndMarkets; 11/04/2018 – ServiceMax from GE Digital to Focus on the Impact of Proactive Maintenance Strategies to the Service Industry at Field Service

Analysts await Revance Therapeutics, Inc. (NASDAQ:RVNC) to report earnings on February, 27. They expect $-0.96 EPS, up 15.79% or $0.18 from last year’s $-1.14 per share. After $-0.91 actual EPS reported by Revance Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.49% negative EPS growth.

Investors sentiment increased to 1.47 in 2018 Q3. Its up 0.16, from 1.31 in 2018Q2. It improved, as 10 investors sold Revance Therapeutics, Inc. shares while 22 reduced holdings. 16 funds opened positions while 31 raised stakes. 32.53 million shares or 1.08% less from 32.89 million shares in 2018Q2 were reported. Swiss Bank & Trust holds 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC) or 51,050 shares. Moreover, Susquehanna Grp Llp has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC). 200 are owned by Prelude Management Lc. Moreover, Tiaa Cref Inv Management Ltd Limited Liability Company has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC). Walleye Trading Ltd Limited Liability Company reported 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). Great West Life Assurance Communications Can, a Manitoba – Canada-based fund reported 2,553 shares. Rhenman & Ptnrs Asset Mgmt Ab accumulated 203,181 shares. Sectoral Asset Incorporated invested in 11,234 shares. Moreover, Geode Ltd Liability Company has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 337,493 shares. Schwab Charles Management invested in 177,926 shares. California State Teachers Retirement Systems holds 0% or 50,206 shares. Northern Tru invested in 438,869 shares. Franklin Incorporated invested in 0.03% or 2.55M shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,193 shares. Deutsche Bancshares Ag stated it has 219,627 shares.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company has market cap of $778.00 million. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It currently has negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.

Since November 9, 2018, it had 0 insider buys, and 4 insider sales for $80,454 activity. $51,899 worth of stock was sold by Allouche Cyril on Friday, November 9.

More notable recent Revance Therapeutics, Inc. (NASDAQ:RVNC) news were published by: which released: “Revance Therapeutics (RVNC) Announces Proposed Approx. $100M Common Share Offering –” on January 15, 2019, also with their article: “Revance up 1% after hours on bullish call at Stifel – Seeking Alpha” published on January 28, 2019, published: “Biocept leads healthcare gainers; Achieve Life Sciences and Revance Therapeutics among losers – Seeking Alpha” on January 16, 2019. More interesting news about Revance Therapeutics, Inc. (NASDAQ:RVNC) were released by: and their article: “Pre-Market Most Active for Jan 17, 2019 : RELX, MS, ACB, AZN, SBGL, QQQ, AMD, PCG, SQQQ, RVNC, AAPL, TVIX – Nasdaq” published on January 17, 2019 as well as‘s news article titled: “UBS likes Lilly in premarket analyst action – Seeking Alpha” with publication date: January 23, 2019.

Among 3 analysts covering Revance Therapeutics (NASDAQ:RVNC), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Revance Therapeutics has $50 highest and $41 lowest target. $41.67’s average target is 134.36% above currents $17.78 stock price. Revance Therapeutics had 3 analyst reports since September 17, 2018 according to SRatingsIntel. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) has “Market Perform” rating given on Monday, September 17 by JMP Securities. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) earned “Buy” rating by Guggenheim on Friday, November 16.

The stock decreased 0.45% or $0.08 during the last trading session, reaching $17.78. About 270,733 shares traded. Revance Therapeutics, Inc. (NASDAQ:RVNC) has declined 29.56% since February 14, 2018 and is downtrending. It has underperformed by 29.56% the S&P500. Some Historical RVNC News: 29/05/2018 – REVANCE THERAPEUTICS INC – REVANCE IS INITIATING A SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER; 21/05/2018 – Revance Therapeutics Presenting at UBS Conference Tomorrow; 16/05/2018 – Revance Therapeutics Presenting at UBS Conference May 22; 19/04/2018 – REVANCE SEES PRODUCT LAUNCH IN 2020, ASSUMING FDA APPROVAL; 24/05/2018 – REVANCE REPORTS PUBLICATION FROM CERVICAL DYSTONIA PHASE 2; 24/05/2018 – Revance: RT002 Achieved High Response Rate, Long-Lasting Effect Across All Treatment Groups and Doses; 01/05/2018 – Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary; 24/05/2018 – Revance Announces Publication of Positive 24-Week Duration of Effect Results From Cervical Dystonia Phase 2 Trial; 18/04/2018 – Retrotope Announces Peer-Reviewed Publication of Positive Phase 1b/2a Findings for RT001 in Friedreich’s Ataxia; 26/03/2018 – Revance to Host Investor Day on April 19, 2018

Moneta Group Investment Advisors Llc increased Vanguard Large Cap (VV) stake by 12,262 shares to 22,394 valued at $2.99M in 2018Q3. It also upped Ishares S&P Smallcap 600 Etf (IJR) stake by 27,890 shares and now owns 230,596 shares. Corporate Cap Tr Inc Com was raised too.

Since November 1, 2018, it had 3 insider purchases, and 0 selling transactions for $2.78 million activity. The insider DSOUZA FRANCISCO bought 60,000 shares worth $499,200. Another trade for 225,000 shares valued at $2.19M was made by CULP H LAWRENCE JR on Thursday, November 1. Another trade for 10,000 shares valued at $94,800 was bought by DIMITRIEF ALEXANDER.

More notable recent General Electric Company (NYSE:GE) news were published by: which released: “General Electric’s Shake-Up Will Add Value – Seeking Alpha” on February 13, 2019, also with their article: “What the Market Missed from General Electric’s Q4 Earnings Report – Yahoo Finance” published on February 11, 2019, published: “GE: Undervalued By About $68 Billion – Seeking Alpha” on February 07, 2019. More interesting news about General Electric Company (NYSE:GE) were released by: and their article: “General Electric: Why You Should Ignore The Noise – Seeking Alpha” published on January 30, 2019 as well as‘s news article titled: “GE Power facing $92B backlog – Atlanta Business Chronicle” with publication date: February 13, 2019.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Institutional Positions Chart